NCT04613817 (SeCoBelChild) is a clinical trial in SARS-CoV-2, sponsored by Sciensano.

Who is sponsoring NCT04613817?

NCT04613817 is sponsored by Sciensano.

What condition does NCT04613817 study?

NCT04613817 studies SARS-CoV-2, SARS-CoV Infection, Covid19.

Is NCT04613817 still recruiting?

NCT04613817 is currently completed. Last updated 13 May 2022.

Last reviewed 2022-05-13 · How we verify

NCT04613817: SeCoBelChild

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sero-prevalence COVID-19 Among Belgian Children

Completed Last updated 13 May 2022

What this trial tests

trial in SARS-CoV-2 in 2,103 participants. Completed in 31 December 2021.

Timeline

3 December 2020

Primary endpoint
17 December 2021

31 December 2021

Quick facts

Lead sponsor	Sciensano
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,103
Start date	3 December 2020
Primary completion	17 December 2021
Estimated completion	31 December 2021
Sites	1 location across Belgium

Conditions studied

SARS-CoV-2 — all drugs for SARS-CoV-2 →
SARS-CoV Infection — all drugs for SARS-CoV Infection →
Covid19 — all drugs for Covid19 →

Sponsor

Sciensano

Who can join

Adults 8 to 14, any sex, with SARS-CoV-2 or SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on studies in China, Iceland, the Netherlands and Italy it seems that children are less affected by SARS-CoV-2 infections and play a lesser role in the dissemination of the SARS-CoV-2 virus. It is unclear to which extend this is due to lesser exposure or an inherent decreased susceptibility to become infected. The low reported number of cases in children can be partially explained by the lower testing rates in the pediatric population. To get insight in the transmission of SARS-CoV-2 virus in school-aged children it is necessary to compile data on infection of SARS-CoV-2 virus in the child and (pre-)adolescent population. The main objective of this study is to determine the sero-prevalence and sero-conversion of antibodies against SARS-CoV-2 in a sample of school-aged children (primary and secondary school) in Belgium at different time points. Additionally this study will gain insight in the incidence of SARS-CoV-2, the proportion of asymptomatic infections with SARS-CoV-2 and the role of COVID-19 infection in household members. It will give us the possibility to investigate potential risk factors for infection. The study population includes primary and secondary school children from two predefined age groups (8-9 and 13-14 years old). These two groups are chosen because studies have shown more pronounced symptoms of infection and disease depending on age and because transmission dynamics also vary by age. The study population will be recruited in all Belgian schools including Brussels-Capital, Flemish and Walloon Region (including the German speaking community). The study is a prospective cohort study. In total there will be 3 testing points with 3 months between each point. The sample size calculation indicated the inclusion of 41 randomly selected primary and 41 secondary schools and in each school 20 randomly selected pupils of the defined age groups. Parents/legal child caregiver will complete a questionnaire at each of the testing points providing basic socio-demographic characteristics (at baseline only) and risk-behavior and health characteristics including presence of symptoms during the time since the previous testing point (at each of the testing points). The questionnaire will be completed through a secured online application during the same week as the child had the saliva sample for serological testing taken. Saliva samples will be sent to the Sciensano laboratory for serological analysis. The child's parent/legal caregiver will be informed of the serological result. Study data will guide the Belgian policy makers in their advices to limit circulation of SARS-CoV-2 in Belgium and more specifically in their advice on measures for school-age children. This data might also be used to guide health authorities that have to decide on vaccination strategies once a vaccine is available; to decide whether children should be included for vaccination to create herd immunity or not.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

SARS-CoV-2 seroprevalence and determinants for salivary seropositivity among pupils and school staff: a prospective cohort study.
Merckx J, Callies M, Kabouche I, Desombere I, et al · · 2023 · cited 3× · PMID 37092673 · DOI 10.1017/s0950268823000584
SARS-CoV-2 infection prevention and control measures in Belgian schools between December 2020 and June 2021 and their association with seroprevalence: a cross-sectional analysis of a prospective cohort study.
Callies M, Kabouche I, Desombere I, Merckx J, et al · · 2023 · cited 2× · PMID 37194008 · DOI 10.1186/s12889-023-15806-5
Measures for infection prevention and control of SARS-CoV-2 in Belgian schools between December 2020 and June 2021: a prospective cohort study
Callies M, Kabouche I, Desombere I, Merckx J, et al · · 2022 · cited 1× · DOI 10.1101/2022.04.12.22273722

Verify or expand the search:

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting

Other Sciensano trials

Trials by the same sponsor.

NCT06007001 — Telerehabilitation and Tele-psychological Support in Cancer Patients eCAN JA · NA · recruiting
NCT04852861 — COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine · Phase 4 · completed
NCT04738695 — SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19) · completed
NCT05373420 — COVID-19 Vaccination Uptake in Belgium : Sociodemographic and Socioeconomic Disparities · completed
NCT04527614 — Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04613817 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sciensano
Last refreshed: 13 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04613817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing